These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24135437)

  • 1. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.
    Osborne JR; Green DA; Spratt DE; Lyashchenko S; Fareedy SB; Robinson BD; Beattie BJ; Jain M; Lewis JS; Christos P; Larson SM; Bander NH; Scherr DS
    J Urol; 2014 May; 191(5):1439-45. PubMed ID: 24135437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pilot study of the diagnostic utility of
    Vlachostergios PJ; Niaz MJ; Thomas C; Christos PJ; Osborne JR; Margolis DJA; Khani F; Bander NH; Scherr DS; Tagawa ST
    Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [
    Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
    Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Lopci E; Saita A; Lazzeri M; Lughezzani G; Colombo P; Buffi NM; Hurle R; Marzo K; Peschechera R; Benetti A; Zandegiacomo S; Pasini L; Lista G; Cardone P; Castello A; Maffei D; Balzarini L; Chiti A; Guazzoni G; Casale P
    J Urol; 2018 Jul; 200(1):95-103. PubMed ID: 29409824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18F-DCFBC Prostate-Specific Membrane Antigen-Targeted PET/CT Imaging in Localized Prostate Cancer: Correlation With Multiparametric MRI and Histopathology.
    Turkbey B; Mena E; Lindenberg L; Adler S; Bednarova S; Berman R; Ton AT; McKinney Y; Eclarinal P; Hill C; Afari G; Bhattacharyya S; Mease RC; Merino MJ; Jacobs PM; Wood BJ; Pinto PA; Pomper MG; Choyke PL
    Clin Nucl Med; 2017 Oct; 42(10):735-740. PubMed ID: 28806263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.
    Pandit-Taskar N; O'Donoghue JA; Morris MJ; Wills EA; Schwartz LH; Gonen M; Scher HI; Larson SM; Divgi CR
    J Nucl Med; 2008 Jul; 49(7):1066-74. PubMed ID: 18552139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate Specific Membrane Antigen Targeted Positron Emission Tomography of Primary Prostate Cancer: Assessing Accuracy with Whole Mount Pathology.
    Bahler CD; Green M; Hutchins GD; Cheng L; Magers MJ; Fletcher J; Koch MO
    J Urol; 2020 Jan; 203(1):92-99. PubMed ID: 31430234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.
    Rowe SP; Gage KL; Faraj SF; Macura KJ; Cornish TC; Gonzalez-Roibon N; Guner G; Munari E; Partin AW; Pavlovich CP; Han M; Carter HB; Bivalacqua TJ; Blackford A; Holt D; Dannals RF; Netto GJ; Lodge MA; Mease RC; Pomper MG; Cho SY
    J Nucl Med; 2015 Jul; 56(7):1003-1010. PubMed ID: 26069305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection Rate of Prostate Specific Membrane Antigen Tracers for Positron Emission Tomography/Computerized Tomography in Prostate Cancer Biochemical Recurrence: A Systematic Review and Network Meta-Analysis.
    Crocerossa F; Marchioni M; Novara G; Carbonara U; Ferro M; Russo GI; Porpiglia F; Di Nicola M; Damiano R; Autorino R; Cantiello F
    J Urol; 2021 Feb; 205(2):356-369. PubMed ID: 32935652
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Farolfi A; Gafita A; Calais J; Eiber M; Afshar-Oromieh A; Spohn F; Barbato F; Weber M; Ilhan H; Cervati V; Wetter A; Hadaschik B; Briganti A; Walz J; Pianori D; Fanti S; Haberkorn U; Herrmann K; Fendler WP
    J Urol; 2019 Dec; 202(6):1174-1181. PubMed ID: 31233369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of (
    Yilmaz U; Komek H; Can C; Altindag S
    Ann Nucl Med; 2019 Aug; 33(8):545-553. PubMed ID: 31069696
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.
    Pandit-Taskar N; O'Donoghue JA; Beylergil V; Lyashchenko S; Ruan S; Solomon SB; Durack JC; Carrasquillo JA; Lefkowitz RA; Gonen M; Lewis JS; Holland JP; Cheal SM; Reuter VE; Osborne JR; Loda MF; Smith-Jones PM; Weber WA; Bander NH; Scher HI; Morris MJ; Larson SM
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2093-105. PubMed ID: 25143071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Predictive Value of Preoperative Negative Prostate Specific Membrane Antigen Positron Emission Tomography Imaging for Lymph Node Metastatic Prostate Cancer.
    Meijer D; de Barros HA; van Leeuwen PJ; Bodar YJL; van der Poel HG; Donswijk ML; Hendrikse NH; van Moorselaar RJA; Nieuwenhuijzen JA; Oprea-Lager DE; Vis AN
    J Urol; 2021 Jun; 205(6):1655-1662. PubMed ID: 33530746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer.
    Rhee H; Thomas P; Shepherd B; Gustafson S; Vela I; Russell PJ; Nelson C; Chung E; Wood G; Malone G; Wood S; Heathcote P
    J Urol; 2016 Oct; 196(4):1261-7. PubMed ID: 27220897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy, Predictive Factors, and Prediction Nomograms for
    Rauscher I; Düwel C; Haller B; Rischpler C; Heck MM; Gschwend JE; Schwaiger M; Maurer T; Eiber M
    Eur Urol; 2018 May; 73(5):656-661. PubMed ID: 29358059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal Timing of Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Biochemical Recurrence after Radical Prostatectomy.
    Luiting HB; van Leeuwen PJ; Remmers S; Donswijk M; Busstra MB; Bakker IL; Brabander T; Stokkel M; van der Poel HG; Roobol MJ
    J Urol; 2020 Sep; 204(3):503-510. PubMed ID: 32149575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.
    Pandit-Taskar N; O'Donoghue JA; Durack JC; Lyashchenko SK; Cheal SM; Beylergil V; Lefkowitz RA; Carrasquillo JA; Martinez DF; Fung AM; Solomon SB; Gönen M; Heller G; Loda M; Nanus DM; Tagawa ST; Feldman JL; Osborne JR; Lewis JS; Reuter VE; Weber WA; Bander NH; Scher HI; Larson SM; Morris MJ
    Clin Cancer Res; 2015 Dec; 21(23):5277-85. PubMed ID: 26175541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.